@prefix this: <http://www.tkuhn.ch/bel2nanopub/RABbESCsfnHPh7xg5HvgFq4dIOW2aaXNNFUalvIKV6dlU> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RABbESCsfnHPh7xg5HvgFq4dIOW2aaXNNFUalvIKV6dlU#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0003824 .
  
  sub:_2 geneProductOf: hgnc:6973;
    a Protein: .
  
  sub:_3 hasAgent: sub:_4;
    a go:0042789 .
  
  sub:_4 geneProductOf: hgnc:11998;
    a Protein: .
  
  sub:_5 occursIn: species:9606;
    rdf:object sub:_3;
    rdf:predicate belv:decreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "cat(p(HGNC:MDM2)) -| tscript(p(HGNC:TP53))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_7;
    pav:version "1.4" .
  
  sub:_6 prov:value "It has been proposed that ARF is expressed only when an E2F signaling threshold is exceeded following oncogenic activation. The main activity of ARF is its ability to bind to p53 inhibitors and to control ribosome biogenesis. Human double minute (HDM2) [mouse double minute 2 (Mdm2) in mouse] and ARF protein binding 1 (BP1)/Mule are two specific E3 ubiquitin ligases that mediate p53 degradation through ubiquitination.";
    prov:wasQuotedFrom pubmed:17118707 .
  
  sub:_7 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:17118707;
    prov:wasDerivedFrom beldoc:, sub:_6 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:48.365+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}